

Systemic Lupus Erythematosus (SLE) Report

Date: 25 November 2009

"Copyright 2009 CBDM.T SARL. All rights reserved. Any unauthorized use or disclosure is prohibited. The information herein was obtained from various sources; we do not guarantee its accuracy or completeness. This research report is prepared for general circulation and is circulated for general information only. It does not have regard to specific investment objectives, financial situation and the particular needs of any particular person who may receive this report. Investors should seek financial advice regarding the appropriateness of investing in any securities or investment and trading strategies discussed or recommended in this report and should understand that the statements regarding future prospects may not be realized. Investors should note that income from such securities, if any, may fluctuate and that each security's price or value may rise or fall. Accordingly, investors may receive back less than originally invested. Past performance is not necessarily a guide to future performance. Neither the information nor any opinion expressed constitutes an offer to buy or sell any securities or options or futures contracts. CBDM.T SARL accepts no responsibility or liability whatsoever for any expense, loss or damages arising out of or in any way connected with the use of all or any part of this report. CBDM.T SARL does not have long or short position in any securities or options of this issue(s)."

Table of Content

Presentation - Global Information	4
Diagnosis, treatment and management.....	7
The Epidemiology of SLE	10
Market	13
Global Autoimmune Market Overview	13
Products	14
Corticosteroids	15
Immunosuppressant Drugs	16
Products in development	17
HydroxyChloriquine (Assistance Publique Hôpitaux de Paris/Sanofi Aventis).....	23
Rosuvastatin + Simvastatin (Ramathibodi Hospital/AstraZeneca).....	25
Belimumab (Human Genome Sciences/GSK/CAT)	26
Clinical Data.....	27
About the Belimumab Phase 3 Development Program	28
Regulatory	42
Rituximab (Genentech)	43
Tacrolimus (Astellas Pharma).....	44
Steroids (prednisone or prednisolone) + MMF Abatacept (Bristol-Myers Squibb)	46
Atorvastatin – Lipitor (Buddhist Tzu Chi General Hospital / Pfizer)	47
Epratuzumab (Immunomedics / UCB).....	48
Immunomedics Data	48
UCB data.....	49
Licensing and General info	51
Clinical Data.....	51
Regulatory	52
TACI-IG (Zymogenetics / Merck Serono)	53
ZYMOGENETICS INC	53
MERCK SERONO SA	57
Prasterone GL701 (Stanford University/ Genelabs).....	58
Licensing and General info	59

Regulatory	59
Etanercept (National Institute of Allergy and Infectious Diseases (NIAID)/ Florida Academic Dermatology Centers)	61
Rontalizumab (rhuMAb IFNalpha) -Omalizumab (Genentech)	62
Edratide (Teva Pharmaceuticals).....	63
Clinical Data	63
IPP-201101 (Immunopharma /Cephalon)	64
IMMUPHARMA PLC	64
CEPHALON INC	65
MEDI-545 - Sifalimumab (Corixa / Medimmune / Medarex)	67
Licensing and General info	67
Clinical Data	68
ABR-215757 (Active Biotech)	69
Clinical Data	69
AMG-623 (Amgen / Anthera Pharmaceuticals).....	70
ETI-104 (Elusis Therapeutics)	71
MTRX-1011A (Tolerx / Genentech)	71
Licensing and General info	72
Clinical Data	72
LUPUSORB (Verto Medical)	72
Clinical Data	73
CPG-52364 (Coley Pharmaceutical).....	73
Clinical Data	73
ANTI-ILT7 (SBI Biotech Co / Medimmune)	74
Licensing and General info	74
C5AR ANTAGONIST (Chemocentryx).....	75
I-3D (Active Biotech/ Chelsea Therapeutics).....	75
Licensing and General info	76
Preclinical Data	76
IFN Alpha Kinoid (Neovacs)	77
MEDI-546 (Medarex / MedImmune).....	78
Licensing and General info	78
IRS-954 (Dynavax).....	79
Preclinical Data.....	79

VLST-007 (VLST Corporation)	80
Products In Discovery	80
Discontinued Development:.....	81
ABETIMUS:.....	81
Cellcept (Aspreva Pharmaceuticals)	81

List of Figures

Figure 1: Possible events contributing to the development of systemic lupus erythematosus	6
Figure 2: Global autoimmune market share by geography in 2006.....	13

List of Tables

Table 1: Diagnostic tools for lupus	7
Table 2: Common Symptoms of Lupus.....	8
Table 3: Estimated SLE prevalence in 2007	10
Table 4: Forecast prevalence of lupus across the seven major markets 2006-2012	10
Table 5: breakdown of the global autoimmune market 2002-2011	14
Table 6: Leading Immonosuppressant in the global autoimmune market 2005-2006.....	15
Table 7: Product in Development for Lupus Therapeutic Area.....	19